Certificate under SEBI (Depositories and Participants) Regulations, 2018
Mankind Pharma received a certificate from KFin Technologies confirming compliance with SEBI regulations regarding dematerialisation/rematerialisation requests for the quarter ended September 30, 2025.
This is a routine compliance filing and has a low impact on the company's operations or stock price.
The announcement is a routine compliance update, and it does not contain any information that would be considered positive or negative.
* Compliance certificate received from KFin Technologies Limited, the Registrar and Share Transfer Agent, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. * The certificate confirms that no requests for dematerialisation / rematerialisation of shares were received during the quarter from July 01, 2025, to September 30, 2025.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.